ArticleBioMed research international2018
Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan.
Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A comprehensive analysis of lung cancer status changes over 10 years: results of Moroccan cohort.BJC reports · 2026Article
- Lung cancer screening uptake in patients with rheumatoid arthritis in community settings.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Comorbidity Burden in Lung Cancer and Malignant Pleural Mesothelioma: Nationwide Database Results of Turkey.Medicina (Kaunas, Lithuania) · 2026Article
- Disease spectrum and comorbidity patterns of malignant neoplasms: a multi-center hospital-based retrospective analysis of inpatient insurance claims data.Frontiers in oncology · 2026Article
- Changes in diagnostic evaluation of patients with lung cancer symptoms.NPJ primary care respiratory medicine · 2025Article
- How do health literacy and chronic disease influence the diagnostic evaluation of patients with lung cancer symptoms?Acta oncologica (Stockholm, Sweden) · 2025Article
- Comorbidity of hypertension and lung cancer: interplay of genetics and environment.Discover oncology · 2025Review
- Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy.Acta pharmaceutica Sinica. B · 2024Review
- Review
- Prevalence of comorbidities and their impact on survival among older adults with the five most common cancers in Taiwan: a population study.Scientific reports · 2023Article
- Article
- Metformin use and lung cancer survival: a population-based study in Norway.British journal of cancer · 2021Article
- Article
- Computerized tomography-Guided Microwave Ablation of Patients with Stage I Non-small Cell Lung Cancers: A Single-Institution Retrospective Study.Journal of clinical imaging science · 2021Article
- Association between Metabolites and the Risk of Lung Cancer: A Systematic Literature Review and Meta-Analysis of Observational Studies.Metabolites · 2020Review
- Article
- Surgical Outcomes in Patients With Centrally Located Non-small Cell Lung Cancer.In vivo (Athens, Greece)Article
- The Influence of Multiple Chronic Conditions on Symptom Clusters in People With Solid Tumor Cancers.Cancer nursingArticle
- Multimorbidity and Its Associations With Anxiety and Depression Among Newly Diagnosed Patients With Breast Cancer: A Retrospective Observational Cohort Study in a US Commercially Insured and Medicare Advantage Population.Cancer control : journal of the Moffitt Cancer CenterObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of comorbidity on lung cancer patients' survival has been widely reported. The aim of this study was to investigate the effects of comorbidity on the establishment of the diagnosis of lung cancer and survival in lung cancer patients in Taiwan by using a nationwide population-based study design. This study collected various comorbidity patients and analyzed data regarding the lung cancer diagnosis and survival during a 16-year follow-up period (1995-2010). In total, 101,776 lung cancer patients were included, comprising 44,770 with and 57,006 without comorbidity. The Kaplan-Meier analyses were used to compare overall survival between lung cancer patients with and without comorbidity. In our cohort, chronic bronchitis patients who developed lung cancer had the lowest overall survival in one (45%), five (28.6%), and ten years (26.2%) since lung cancer diagnosis. Among lung cancer patients with nonpulmonary comorbidities, patients with hypertension had the lowest overall survival in one (47.9%), five (30.5%), and ten (28.2%) years since lung cancer diagnosis. In 2010, patients with and without comorbidity had 14.86 and 9.31 clinical visits, respectively. Lung cancer patients with preexisting comorbidity had higher frequency of physician visits. The presence of comorbid conditions was associated with early diagnosis of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.